Avisos y alertas de síntomas o signos de pre trombosis en la mujer transexual hormonada (página 2)

18. Crenshaw BS, Harrington RA, Tcheng JE. Agentes antiplaquetarios Novel: los inhibidores de la glicoproteína IIb / IIIa. Exp Opin Drogas Invest . 1995 ; 4 : 1033 -1044.

19. Daniele S, Schepens CL, Daniele C, Angeletti G. Fundus abnormalities in Cushing's disease: a preliminary report. Ophthalmol. 1995;209(2):88-91.

20. Daniels SR, Lipman MJ, Burke MJ, Loggie JM. Determinants of retinal vascular abnormalities in children and adolescents with essential hypertension. J Hum Hypertens. 1993;7(3):223-8.

21. Deltenre P, Denninger MH, Hillaire S, Guillin MC, Casadevall N, Briere J, Erlinger S, Valla DC. Factor V Leiden related Budd-Chiari syndrome. Gut. 2001;48:264–268.

22. Dulak J; Polus M; Guevara I; Polus A; Hartwich J; Dembinska-Kiec A. Regulation of inducible nitric oxide synthase (iNOS) and GTP cyclohydrolase I (GTP-CH I) gene expression by ox-LDL in rat vascular smooth muscle cells. J Physiol Pharmacol. 1997;48:689–697

23. Essler M, Retzer M, Bauer M, Heemskerk JW, Aepfelbacher M, Siess W. Midly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase. J Biol Chem. 1999;274:30361-4.

24. Fernández-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1562-9.

25. Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, et al. Treatment of submassive pulmonary embolism ¿with tenecteplase or placebo: cardiopulmonary outcomes at 3 months multicenter double-blind, placebo controlled randomized trial. J Thromb Haemost 2014;12:459-68.

26. Klok FA, Niemann C, Dellas C, Hasenfuß G, Konstantinides S, Lankeit M. Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism. J Thromb Thrombolysis 2016;41:312-20

27. Kutschbach P,Wolf S, Sieveking M, Ittel TH, Schulte K, Reim M. Retinal capillary density in patients with arterial hypertension: 2-year follow-up. Graefes Arch Clin Exp Ophthalmol. 1996;236:410-4.

28. Lafaut BA, De Vriese AS, Stulting AA. Fundus fluoresce in angiography of patients with severe hypertensive nephropathy.Graefes Arch Clin Exp Ophthalmol. 1997;235:749-54.

29. Levine, S., Welch, K. The spectrum of neurologic disease associated with anticardiolipin antibodies. Arch. Neurol. 1987; 44; 876-880.

30. Lonn, L.I.; Hoyt, W.F.: Papillophlebitis: A cause of protracted yet benign optic disc edema. Eye Ear Nose Throat Monthly, 1966;45:62.

31. Lucotte G, la genética de poblaciones de G. Mercier factor V de Leiden en Europa. Blood Cells Mol Dis. 2001; 27 : 362-367.

32. Ludemann P, Nabavi DG, Junker R, et al. Mutación factor V Leiden es un factor de riesgo para la trombosis venosa cerebral: un estudio de casos y controles de 55 pacientes. Accidente cerebrovascular. 1998 ; 29 : 2507 -2510

Ludemann P, Nabavi DG, Junker R, et al. Mutación factor V Leiden es un factor de riesgo para la trombosis venosa cerebral: un estudio de casos y controles de 55 pacientes. Accidente cerebrovascular . 1998 ; 29 : 2507 -2510.

33. Lussana F, Dentali F, Ageno W, Kamphuisen PW. Venous thrombosis at unusual sites and the role of thrombophilia. Semin Thromb Hemost 2007; 33(6):582-587

34. Luxenberg, M.N.; Mausolf, F.A.: Retinal circulation in the hyperviscosity syndrome. Am J Ophthalmol, 1970;70:588.

35. Magargal, L.E.; Brown, G.C.; Augsburger, J.J.; Parrish, R.K. II: Neovascular glaucoma following central retinal vein obstruction. Ophthalmology, 1981;88:1095-1101.

36. Mai C, Hunt D. Upper-extremity deep venous thrombosis: a review. Am J Med 2011; 124(5): 402-407

37. Margaglione M, Brancaccio V, Giuliani N, D'Andrea G, Cappucci G, Iannaccone L, Vecchione G, Grandone E, Di Minno G. Increased risk for venous thrombosis in carriers of the prothrombin G–>A20210 gene variant. Ann Intern Med. 1998;129:89–93.

38 Margaglione M, V Brancaccio, Giuliani N, D'Andrea G, G Cappucci, Iannaccone L, G Vecchione, Grandone E, Di minno G. Aumento del riesgo de trombosis venosa en los portadores de la protrombina G – & gt; variante del gen A20210 . Ann Intern Med. 1998; 129 : 89-93.

39. Martinelli I, G Landi, Merati G, R Cella, Tosetto A, Mannucci PM. Mutación del factor V gen es un factor de riesgo para la trombosis venosa cerebral. Thromb Haemost . 1996 ; 75 : 393 -394.

40. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Perfil farmacodinámico del tratamiento con abciximab corto plazo demuestra la inhibición plaquetaria prolongado con la recuperación gradual del bloqueo de los receptores GP IIb / IIIa. La circulación . 1998 ; 97 : 1680 -1688.

41. Matei D, B Brenner, Marder VJ. Adquiridos síndromes trombofilia. Sangre Rev. 2001; 15 : 31-48

42. Mier J, Sánchez P, Blanco R, Rodríguez J, Martínez V. Angiographic and surgical approach to acute mesenteric ischemia. A prospective study. Abstract # 2177 The Society for Surgery of the Alimentary Tract. Fortieth annual meeting 1999; 226: 16-19.

43. Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J 1997;134:69-72.

44. Mohanty D, S Shetty, Ghosh K, Pawar A, trombofilia hereditaria P. Abraham como una de las causas del síndrome de Budd-Chiari: un estudio de la India Occidental. Hepatología. 2001; 34 : 666-670

45 N, Boekstegers P, Müller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014;129:479-86.

46. Orozco H et al: Is splenectomy necessary in devascularization procedures for treatment of bleeding portal hypertension? Arch Surg 1998;133:36-8.

47. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol. 1996;16:742–748.

48. Pagliuca A, Mufti GJ, Janossa-Tahernia M, S Eridani, Westwood NB, Thumpston J, Sawyer B, R Sturgess, Williams R. En estudios de cultivo de la colonia y cromosómicas in vitro en la trombosis de la vena hepática y porta – la posible evidencia de una mieloproliferativo estado oculto. QJ Med. 1990; 76 : 981-989.

49. PH Franco RF, Reitsma. Factores de riesgo genético de la trombosis venosa. Hum Genet. 2001; 109 : 369-384

50. Phillips DR, Agin PP. Defectos de membrana de plaquetas en Enfermedad de Glanzmann: evidencias para la disminución de las cantidades de dos glicoproteínas principales. J Clin Invest . 1977 ; 60 : 535 -545.

51. Piazza G, Hohlfelder B, Jaff MR, Ouriel K, Engelhardt TC, Sterling KM. A prospective, single-arm, multicenter trial of ultrasoundfacilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism. SEATTLE II. JACC Cardiovasc

Intervent 2015;8:1382-92.

52. Polderman KH, Gooren LJ, Asscheman H, Bakker A & Heine RJ. Induction of insulin resistance by androgens and estrogens. Journal of Clinical Endocrinology and Metabolism 1994 79 265–271.

53. Post MS, Christella M, Thomassen LG, van der Mooren MJ, Van Baal WM, Rosing J, Kenemans P & Stehouwer CD. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 1116–1121.

54. Pronzato P, Rondini M. Hormonotherapy of Advanced Prostate Cancer. Ann Oncol 2005;16(Suppl 4):iv80-84.

55. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Koopersberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM & Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 2002 288 321–333.

56. Saitoh M, Matsuo K, Momoto S, KondohT, Yanagawa T, Katoh Y, Hasegawa K. Relationship between left ventricular hypertrophy and renal and retinal damage in untreated patients with essential hypertension Intern Med 1998;37(7):576-80.

57. Saposnik G, Barinagarrementeria F, Brown RD, Jr. Et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42(4): 1158-1192. [

58. Sas, G., Petö, I., Bánheghy, D., et als. Heterogeneity of the classical antithrombin III deficience. Thrombosis and Hemostasis 1980; 43: 133-136.

59. Schulman S, Lindmarker P, Holmström M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4(4):734-742.

60. Schulman S, Rhedin AS, Lindmarker P, et al;; Duration of Anticoagulation Trial Study Group Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332(25):1661-1665.

61. Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H; THRIVE III Investigators THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349(18):1713-1721.

62. Shrivastava S, Ridker PM, Glynn RJ, et al. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2006;4(6):1208-1214

63. Stanton AV, Mullaney P, Mee F, O"Brien ET, O"Malley K. A method of quantifying retinal microvascular alterations associated with blood pressure and age. J Hypertens. 1995;13:41-8.

64. Stevenson, R., Burton, R., Ferianto, G., et als. Hazards of oral anticoagulants during pregnancy. J.A.M.A. 1980; 243: 1549-1551.

65. Stroes E; Hijmering M; Vanzandvoort M; Wever R; Rabelink TJ; Vanfaassen EE. Origin of superoxide production by endothelial nitric oxide synthase. FEBS Lett. 1998;438:161–164.

66. Stroes, E; Kastelein J; Cosentino F; Erkelens W; Wever R; Koomans H; Luscher T; Rabelink. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997;99:41-46. [ Links ]

67. Stroes, E; Kastelein, J; Cosentino, F; Erkelens, W; Wever, R; Koomans, H; Luscher, T; Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J. Clin Invest; 1997; 99: 41-46

68. Teichert AM; Miller TL; Tai SC; Wang Y; Bei X; Robb GB; Phillips MJ; Marsden PA. In vivo expression profile of an endothelial nitric oxide synthase promoter-reporter transgene. Am J Physiol Heart Circ Physiol. 2000; 278:H1352-H1361

69. Thaler, E., Lechner, K. Antithrombin III deficiency and thromboembolism. Clin. Hematol. 1981; 10: 369-390.

70. Thomson, L;Trujillo, M; Telleri, R; Radi, R. Kinetics of cytochromec21 oxidation by peroxynitrite: implications for superoxide measurements in nitric oxide-producing biological systems. Arch Biochem. Biophys. 1995M;319:491- 497

71. Ting, H.H; Timimi, F.K; Boles, K; Creager, S; Ganz, P; Creager, M.A. Vitamin C acutely improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. Circulation. 1995; 92(Suppl1):1747

72. Torres JD, Cardona H, Alvarez L et al. Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population. Am J Hematol 2006; 81(12): 933-937.

73. Tseng YZ, Tseng CD, Lo HM, Chiang FT, Hsu KL. Characteristic abnormal findings of ambulatory blood pressure indicative of hypertensive target organ complications. Eur Heart J. 1994;15(8):1037-43.

74. Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008;149(7):481-490.

75. von Kaulla, E., von Kaulla, K. Antithrombin III and disease. Am. J. Clin. Pathol. 1967; 48(1): 69-80.

76. Weenink, G., Kahle, L., Lamping, R., et als. Antithrombin III in oral contraceptive users and during normotensive pregnancy. Acta Obstet. Gynecol. Scand. 1984; 63: 57-61.

77. Weih M, B Vetter, Castell S, S Ziemer, Kulozik AE, Einhaupl KM. Trombofilia hereditaria en la trombosis venosa cerebral. Cerebrovasc Dis . 2000 ; 10 : 161 -162.

78. Weinstein, C., Miller, M., Axtens, R. Livedo reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erithematosus. Arch. Dermatol. 1987; 123: 596-599.

79. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107(23 Suppl 1): I4-I8

80. Winter, J., Fenech, A., Ridley, W. Familial antithrombin III deficiency. Q. J. Med. 1982; 51: 373-395

81. Wolf S, Arend O, Schulte K, Ittel TH, Reim M. Quantification of retinal capillary density and flow velocity in patients with essential hypertension. Hypertension. 1994;23:464-7.

82. Yu T, Mitchell P, Berry G, Li W,Wang JJ. Retinopathy in older persons without diabetes and its relationship to hypertension. Arch Ophthalmol. 1998;116:83-9

Autor:

Dra. Mireille Emmanuelle Brambila

Higiene mental – Trastornos y enfermedades somáticas.

Psiquiatría somática.

Mexicali Baja California.

México (marzo, ,2017)